Latest Corporate Restructuring News

Page 1 of 47
Being AI is preparing to transfer 57% of its issued shares to existing shareholders while moving a 14.4% stake to Excalibur Capital Partners. The transactions are due to complete on 12 October, when the company will also receive a new chair and board.
Sophie Babbage
Sophie Babbage
2 Oct 2026
Investor Centre’s FY2025 report lays bare the financial strain behind its proposed revival: revenue collapsed, cash fell to just $3,320 and liabilities exceeded assets by $3.81 million. The company is now relying on an unsecured Lake Volta Investments facility and a non-binding restructuring plan after its brokerage subsidiary lost its AFSL.
Claire Turing
Claire Turing
1 Oct 2026
MCS Services has completed the sale of its Traffic Business and now has no operating business, while its ASX securities remain suspended pending a possible recompliance transaction. The company reported $1.77 million in cash at 30 June 2026, but also faces a $495,000 legal settlement and no recurring operating revenue.
Victor Sage
Victor Sage
30 Sept 2026
Energy World Corporation has reported a US$448.2 million FY2026 loss after impairing its Pagbilao power plant and Australian assets, while the group’s survival remains tied to completing a staged US$350 million turbine sale. The audited report also recasts the Pagbilao LNG Hub as the centrepiece of the company’s next phase, but flags material uncertainty around going concern.
Maxwell Dee
Maxwell Dee
30 Sept 2026
Arena REIT delivered higher earnings, distributions and asset values in FY2026, but the failure of a major childcare tenant has forced a sharp reset in its near-term outlook. Edge Early Learning accounts for about 14% of rental income and is now in voluntary administration after missing rent.
Victor Sage
Victor Sage
29 Sept 2026
Cynata Therapeutics (ASX:CYP) has reported a $9.25 million loss, negative net assets and a material uncertainty over going concern after its two major clinical trials failed to demonstrate efficacy. The company has since cut its workforce to zero, shifted management to the board and secured a $600,000 R&D tax incentive loan while it considers the future of its Cymerus platform.
Ada Torres
Ada Torres
28 Sept 2026
Alfabs Australia’s FY26 reset preserved free cash flow despite a sharp earnings decline, while Mining growth and debt refinancing form the bridge to a potential dividend restart. The company enters FY27 leaner, but the plan still depends on execution, cash conversion and Phase II debt restructuring.
Victor Sage
Victor Sage
25 Sept 2026
HyTerra says it has cut recurring corporate overheads by 30% before new initiatives, or 21% after including them, while reshaping its board and management. The geologic hydrogen explorer is also seeking approval for a 20:1 share consolidation and progressing a sponsored US ADR program without raising new capital.
Maxwell Dee
Maxwell Dee
24 Sept 2026
AngloGold Ashanti has exercised early an option to acquire specified Lake Carey tenements from Matsa Resources for a fixed A$55 million, although most of the consideration remains conditional. The deal arrives as Matsa refinances existing debt, manages an operational review and remains suspended from trading.
Maxwell Dee
Maxwell Dee
22 Sept 2026
Range International has replaced CEO Russell Kennett with Executive Chairman Richard Jenkins on an interim basis, with Jenkins to spend more time overseeing the company’s Indonesian operations. The restructure is expected to cut costs by up to 50%, although the company has not disclosed a baseline or implementation timetable.
Victor Sage
Victor Sage
14 Sept 2026
Lithium Plus Minerals has significantly upgraded its Lei Lithium Project resource and secured a 20-year mining lease, positioning the company for near-term development and commercialisation.
Maxwell Dee
Maxwell Dee
4 Sept 2026
Invex Therapeutics posted a $1.35 million net loss for FY2026, driven by expanded R&D efforts and a deepening collaboration with Tessara Therapeutics targeting neurological diseases including Alzheimer’s. The company renewed its orphan drug status in Europe and restructured its board during the year.
Ada Torres
Ada Torres
31 Aug 2026

Browse the archive

Full archive